12.11
-0.09 (-0.74%)
| Previous Close | 12.20 |
| Volume | 217,211 |
| Price / Sales | 5.06 |
| Price / Book | 3.52 |
| 52 Weeks Range |
| Profit Margin | -149.57% |
| Operating Margin (TTM) | -164.32% |
| Diluted EPS (TTM) | -4.53 |
| Quarterly Revenue Growth (YOY) | -12.50% |
| Total Debt/Equity (MRQ) | 231.07% |
| Current Ratio (MRQ) | 5.29 |
| Operating Cash Flow (TTM) | -55.46 M |
| Levered Free Cash Flow (TTM) | -72.37 M |
| Return on Assets (TTM) | -17.33% |
| Return on Equity (TTM) | -74.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Enanta Pharmaceuticals, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | -1.17 |
|
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.57% |
| % Held by Institutions | 87.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Spruce Street Capital Lp | 30 Jun 2026 | 1,088,731 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |